Wilfred Jaeger
Directeur/Membre du Conseil chez NEURONETICS, INC.
Fortune : 487 742 $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Rami Elghandour | M | 45 |
Caremessage
Caremessage Medical/Nursing ServicesHealth Services Caremessage is a 501c3 non-profit organization that focuses on improving health outcomes and reducing the cost of care for underserved populations. The private company is based in San Francisco, CA, and the CEO of the company is Vineet Singal. The company offers a unique mobile messaging technology that enables health centers to remind patients of upcoming appointments, fill gaps in care, provide education, and allow one-to-one provider-to-patient communications. The company operates under the guiding principle that everyone should have access to quality healthcare, regardless of their ability to pay, where they live, and the language they speak. Caremessage has reached more than 30 million underserved patients and helps safety net organizations be more efficient with their time. | 13 ans |
D. Grossman | M | 63 | 5 ans | |
Stephen Furlong | M | 60 | - | |
W. Macan | M | 51 | 4 ans | |
Robert Cascella | M | 69 | 3 ans | |
Kashif Rashid | M | 50 | 7 ans | |
Keith Sullivan | M | 65 | 4 ans | |
Christopher Christoforou | M | 54 | 8 ans | |
Joe Capper | M | 60 | 1 ans | |
Farhad Khosravi | M | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | 22 ans |
Hank Plain | M | 66 |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | - |
Susan M. Aloyan | F | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | - |
Sara Grubbs | F | - | 4 ans | |
Tim F. Howe | M | 66 |
Healthinvest Equity Partners
Healthinvest Equity Partners Investment ManagersFinance Healthinvest Equity Partners (Healthinvest Equity) is a venture capital firm founded in 2013 by Wilfred Jaeger M.D. The firm is headquartered in Westport, Connecticut. | 11 ans |
Susan Siegel | F | 63 | 4 ans | |
Shawn McCormick | M | 59 | 10 ans | |
Frank Fischer | M | 82 | 12 ans | |
Megan Rosengarten | F | 47 | 3 ans | |
Vineet Singal | M | - |
Caremessage
Caremessage Medical/Nursing ServicesHealth Services Caremessage is a 501c3 non-profit organization that focuses on improving health outcomes and reducing the cost of care for underserved populations. The private company is based in San Francisco, CA, and the CEO of the company is Vineet Singal. The company offers a unique mobile messaging technology that enables health centers to remind patients of upcoming appointments, fill gaps in care, provide education, and allow one-to-one provider-to-patient communications. The company operates under the guiding principle that everyone should have access to quality healthcare, regardless of their ability to pay, where they live, and the language they speak. Caremessage has reached more than 30 million underserved patients and helps safety net organizations be more efficient with their time. | - |
Mark Wan | M | 58 |
Three Arch Partners
Three Arch Partners Investment ManagersFinance Three Arch Partners (TAP) is a venture capital firm founded in 1993 by Thomas Fogarty and Wilfred Jaeger. The firm is headquartered in San Mateo, California. | 31 ans |
Glenn Muir | M | 65 | 7 ans | |
Kevin O'Boyle | M | 68 | 5 ans | |
John Bakewell | M | 62 | 4 ans | |
Elizabeth Weatherman | F | 64 | 5 ans | |
Donald Middlebrook | M | 73 | 4 ans | |
Karen Prange | F | 60 | 5 ans | |
Sheryl Conley | F | 63 | 5 ans | |
David Caraway | M | 67 | 10 ans | |
Adrian Aguilera | M | - |
Caremessage
Caremessage Medical/Nursing ServicesHealth Services Caremessage is a 501c3 non-profit organization that focuses on improving health outcomes and reducing the cost of care for underserved populations. The private company is based in San Francisco, CA, and the CEO of the company is Vineet Singal. The company offers a unique mobile messaging technology that enables health centers to remind patients of upcoming appointments, fill gaps in care, provide education, and allow one-to-one provider-to-patient communications. The company operates under the guiding principle that everyone should have access to quality healthcare, regardless of their ability to pay, where they live, and the language they speak. Caremessage has reached more than 30 million underserved patients and helps safety net organizations be more efficient with their time. | - |
Usha Periyanayagam | F | - |
Caremessage
Caremessage Medical/Nursing ServicesHealth Services Caremessage is a 501c3 non-profit organization that focuses on improving health outcomes and reducing the cost of care for underserved populations. The private company is based in San Francisco, CA, and the CEO of the company is Vineet Singal. The company offers a unique mobile messaging technology that enables health centers to remind patients of upcoming appointments, fill gaps in care, provide education, and allow one-to-one provider-to-patient communications. The company operates under the guiding principle that everyone should have access to quality healthcare, regardless of their ability to pay, where they live, and the language they speak. Caremessage has reached more than 30 million underserved patients and helps safety net organizations be more efficient with their time. | - |
Roderick MacLeod | M | 57 | 4 ans | |
Rick Grubbs | M | - | - | |
Stephen Mason | M | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | - |
David L. Steffy | M | 80 |
Healthinvest Equity Partners
Healthinvest Equity Partners Investment ManagersFinance Healthinvest Equity Partners (Healthinvest Equity) is a venture capital firm founded in 2013 by Wilfred Jaeger M.D. The firm is headquartered in Westport, Connecticut. | - |
Leo Nelson Hopkins | M | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | - |
Carole Roth | F | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | 15 ans |
Glenn Julyan | M | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | 16 ans |
Ariel Klein Sutton | M | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | 16 ans |
Cory Anderson | M | - | 3 ans | |
Todd Cushman | M | - | 3 ans | |
Brian Armijo | M | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | - |
Harsh P. Patel | M | - |
Caremessage
Caremessage Medical/Nursing ServicesHealth Services Caremessage is a 501c3 non-profit organization that focuses on improving health outcomes and reducing the cost of care for underserved populations. The private company is based in San Francisco, CA, and the CEO of the company is Vineet Singal. The company offers a unique mobile messaging technology that enables health centers to remind patients of upcoming appointments, fill gaps in care, provide education, and allow one-to-one provider-to-patient communications. The company operates under the guiding principle that everyone should have access to quality healthcare, regardless of their ability to pay, where they live, and the language they speak. Caremessage has reached more than 30 million underserved patients and helps safety net organizations be more efficient with their time. | 13 ans |
Rob Kuhling | M | - |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | 24 ans |
Jeani Delagardelle | F | 67 |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | - |
Gregory Mark Weinhoff | M | 53 |
Healthinvest Equity Partners
Healthinvest Equity Partners Investment ManagersFinance Healthinvest Equity Partners (Healthinvest Equity) is a venture capital firm founded in 2013 by Wilfred Jaeger M.D. The firm is headquartered in Westport, Connecticut. | - |
Myles D. Greenberg | M | 56 |
Healthinvest Equity Partners
Healthinvest Equity Partners Investment ManagersFinance Healthinvest Equity Partners (Healthinvest Equity) is a venture capital firm founded in 2013 by Wilfred Jaeger M.D. The firm is headquartered in Westport, Connecticut. | - |
Jeff J. Collinson | M | - |
Healthinvest Equity Partners
Healthinvest Equity Partners Investment ManagersFinance Healthinvest Equity Partners (Healthinvest Equity) is a venture capital firm founded in 2013 by Wilfred Jaeger M.D. The firm is headquartered in Westport, Connecticut. | - |
Jeffrey G. Gold | M | 76 |
Access Closure, Inc.
Access Closure, Inc. Medical SpecialtiesHealth Technology Access Closure, Inc. manufactures and distributes medical devices for cardiovascular and peripheral vascular markets. Its products include Mynx ace, Mynx grip, Mynx sealant technology and flash ostial system. The company was in founded in 2002 by Farhad Khosravi and is headquartered in Santa Clara, CA. | - |
Lisa Metzner-Rosas | F | - | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Peter Donato | M | 53 | 2 ans | |
Brian E. Farley | M | 66 | 12 ans | |
David B. Johnston | M | - |
Phoenix Partners (Washington)
Phoenix Partners (Washington) Investment ManagersFinance Founded in 1982 by Stuart C. Johnston, Phoenix Partners is a venture capital limited partnership located in Seattle, Washington. | 20 ans |
David Neil King | M | 56 |
North American Scientific, Inc.
North American Scientific, Inc. Electronic Equipment/InstrumentsElectronic Technology North American Scientific, Inc. manufactures and markets medical devices for the radiation oncology community. It offers intensity modulated and image guided radiation therapy products and services, as well as brachytherapy seeds used in the treatment of prostate cancer. The company also offers iodine-based and palladium-based implantable brachytherapy seeds for the treatment of prostate cancer. It provides a line of brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. The company manufactures other radio isotopic products used in various medical, environmental, research and industrial applications. North American Scientific was incorporated in 1990 and is headquartered in Chatsworth, CA. | 9 ans |
Christopher A. Thatcher | M | 59 | 6 ans | |
Bruce Shook | M | 65 | 24 ans | |
Roderick A. Young | M | 80 |
North American Scientific, Inc.
North American Scientific, Inc. Electronic Equipment/InstrumentsElectronic Technology North American Scientific, Inc. manufactures and markets medical devices for the radiation oncology community. It offers intensity modulated and image guided radiation therapy products and services, as well as brachytherapy seeds used in the treatment of prostate cancer. The company also offers iodine-based and palladium-based implantable brachytherapy seeds for the treatment of prostate cancer. It provides a line of brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. The company manufactures other radio isotopic products used in various medical, environmental, research and industrial applications. North American Scientific was incorporated in 1990 and is headquartered in Chatsworth, CA.
Three Arch Partners
Three Arch Partners Investment ManagersFinance Three Arch Partners (TAP) is a venture capital firm founded in 1993 by Thomas Fogarty and Wilfred Jaeger. The firm is headquartered in San Mateo, California. | 3 ans |
Barclay Nicholson | F | - |
Three Arch Partners
Three Arch Partners Investment ManagersFinance Three Arch Partners (TAP) is a venture capital firm founded in 1993 by Thomas Fogarty and Wilfred Jaeger. The firm is headquartered in San Mateo, California. | 17 ans |
Conrad Wang | M | - |
Three Arch Partners
Three Arch Partners Investment ManagersFinance Three Arch Partners (TAP) is a venture capital firm founded in 1993 by Thomas Fogarty and Wilfred Jaeger. The firm is headquartered in San Mateo, California. | - |
L. Michael Cutrer | M | 67 |
North American Scientific, Inc.
North American Scientific, Inc. Electronic Equipment/InstrumentsElectronic Technology North American Scientific, Inc. manufactures and markets medical devices for the radiation oncology community. It offers intensity modulated and image guided radiation therapy products and services, as well as brachytherapy seeds used in the treatment of prostate cancer. The company also offers iodine-based and palladium-based implantable brachytherapy seeds for the treatment of prostate cancer. It provides a line of brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. The company manufactures other radio isotopic products used in various medical, environmental, research and industrial applications. North American Scientific was incorporated in 1990 and is headquartered in Chatsworth, CA. | 18 ans |
Ali Behbahani | M | 47 | 5 ans | |
Lisa Earnhardt | F | 54 | 4 ans | |
Paulina Hill | M | 42 | 2 ans | |
Michael W. Hall | M | 76 | - | |
Gregory Harper | M | 63 | 5 ans | |
Julie Dewey | F | - | 3 ans | |
Peter Bisgaard | M | 50 | 2 ans | |
James Evangelista | M | - |
Three Arch Partners
Three Arch Partners Investment ManagersFinance Three Arch Partners (TAP) is a venture capital firm founded in 1993 by Thomas Fogarty and Wilfred Jaeger. The firm is headquartered in San Mateo, California. | 10 ans |
Bradford E. Gliner | M | 58 | 9 ans | |
Stephen M. Campe | M | 59 | 7 ans | |
Nick B. Pliam | M | 72 | 6 ans | |
Ron Hunt | M | 59 | 4 ans | |
John Barry Rush | M | 64 |
North American Scientific, Inc.
North American Scientific, Inc. Electronic Equipment/InstrumentsElectronic Technology North American Scientific, Inc. manufactures and markets medical devices for the radiation oncology community. It offers intensity modulated and image guided radiation therapy products and services, as well as brachytherapy seeds used in the treatment of prostate cancer. The company also offers iodine-based and palladium-based implantable brachytherapy seeds for the treatment of prostate cancer. It provides a line of brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. The company manufactures other radio isotopic products used in various medical, environmental, research and industrial applications. North American Scientific was incorporated in 1990 and is headquartered in Chatsworth, CA. | 2 ans |
Richard Pops | M | 62 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 ans |
Richard H. Aldrich | M | 69 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 ans |
Peter Elliott | M | 64 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Brad H. Vale | M | 72 | 7 ans | |
James W. Klingler | M | 76 |
North American Scientific, Inc.
North American Scientific, Inc. Electronic Equipment/InstrumentsElectronic Technology North American Scientific, Inc. manufactures and markets medical devices for the radiation oncology community. It offers intensity modulated and image guided radiation therapy products and services, as well as brachytherapy seeds used in the treatment of prostate cancer. The company also offers iodine-based and palladium-based implantable brachytherapy seeds for the treatment of prostate cancer. It provides a line of brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. The company manufactures other radio isotopic products used in various medical, environmental, research and industrial applications. North American Scientific was incorporated in 1990 and is headquartered in Chatsworth, CA. | 4 ans |
Patrick Schmitz | M | 64 | - | |
Olivier Taelman | M | 54 | 2 ans | |
Katherine Bock | F | - | 6 ans | |
Matthew McCarthy | M | - | - | |
Clay Davis | M | - | - | |
Balakrishnan Shankar | M | 58 | 1 ans | |
Divyasmita Ghatak | F | 54 | 3 ans | |
Richard Carter | M | 53 | 10 ans | |
Neeraj Teotia | M | 49 | 7 ans | |
Roger Xie | M | 54 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 3 ans |
Mike P. Chuisano | M | - | - | |
Mike K. Kaplan | M | 58 |
Three Arch Partners
Three Arch Partners Investment ManagersFinance Three Arch Partners (TAP) is a venture capital firm founded in 1993 by Thomas Fogarty and Wilfred Jaeger. The firm is headquartered in San Mateo, California. | 17 ans |
Michael Enxing | M | 57 | 5 ans | |
Doug Alleavitch | M | 63 | - | |
Paul Friedman | M | 81 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Troy A. Barring | M | 64 |
North American Scientific, Inc.
North American Scientific, Inc. Electronic Equipment/InstrumentsElectronic Technology North American Scientific, Inc. manufactures and markets medical devices for the radiation oncology community. It offers intensity modulated and image guided radiation therapy products and services, as well as brachytherapy seeds used in the treatment of prostate cancer. The company also offers iodine-based and palladium-based implantable brachytherapy seeds for the treatment of prostate cancer. It provides a line of brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. The company manufactures other radio isotopic products used in various medical, environmental, research and industrial applications. North American Scientific was incorporated in 1990 and is headquartered in Chatsworth, CA. | 1 ans |
Daniel Guthrie | M | 47 | 2 ans | |
Tiba Aynechi | M | 48 | 1 ans | |
Jeffrey Capello | M | 69 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Leslie Bottorff | F | - | 10 ans | |
Stephen Kraus | M | 47 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 2 ans |
Richard Yu-Tsang Lin | M | - |
Three Arch Partners
Three Arch Partners Investment ManagersFinance Three Arch Partners (TAP) is a venture capital firm founded in 1993 by Thomas Fogarty and Wilfred Jaeger. The firm is headquartered in San Mateo, California. | 13 ans |
Lori Ciano | F | 61 | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Wilfred Jaeger
- Réseau Personnel